INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Consensus Price Target from Analysts

INmune Bio, Inc. (NASDAQ:INMB) has been given a consensus recommendation of “Buy” by the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $22.80.

Several research firms recently weighed in on INMB. Scotiabank upped their price target on shares of INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, February 11th. RODMAN&RENSHAW upgraded shares of INmune Bio to a “strong-buy” rating in a research report on Tuesday, January 28th. Rodman & Renshaw began coverage on shares of INmune Bio in a research note on Tuesday, January 28th. They set a “buy” rating and a $23.00 price objective for the company. Alliance Global Partners began coverage on shares of INmune Bio in a research note on Monday, October 21st. They set a “buy” rating and a $20.00 price objective for the company. Finally, Maxim Group upped their price objective on shares of INmune Bio from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, February 13th.

INmune Bio Stock Down 1.3 %

INMB opened at $9.18 on Thursday. INmune Bio has a twelve month low of $4.32 and a twelve month high of $14.49. The company has a 50-day moving average price of $6.69 and a 200 day moving average price of $6.11. The company has a market cap of $203.52 million, a PE ratio of -4.21 and a beta of 1.87.

Hedge Funds Weigh In On INmune Bio

A number of hedge funds have recently made changes to their positions in INMB. Laird Norton Wetherby Trust Company LLC grew its position in shares of INmune Bio by 3.8% in the 4th quarter. Laird Norton Wetherby Trust Company LLC now owns 34,100 shares of the company’s stock valued at $159,000 after buying an additional 1,250 shares during the last quarter. Financial Advocates Investment Management boosted its holdings in shares of INmune Bio by 17.4% in the third quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock valued at $73,000 after acquiring an additional 2,000 shares in the last quarter. Wells Fargo & Company MN lifted its stake in shares of INmune Bio by 51.0% in the fourth quarter. Wells Fargo & Company MN now owns 6,377 shares of the company’s stock valued at $30,000 after purchasing an additional 2,155 shares during the period. Rhumbline Advisers lifted its stake in shares of INmune Bio by 16.9% in the fourth quarter. Rhumbline Advisers now owns 16,744 shares of the company’s stock valued at $78,000 after purchasing an additional 2,424 shares during the period. Finally, Barclays PLC raised its position in INmune Bio by 10.2% during the fourth quarter. Barclays PLC now owns 32,019 shares of the company’s stock worth $150,000 after acquiring an additional 2,975 shares during the last quarter. Hedge funds and other institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.